Trinity Biotech Reports Q4 2025 Revenue Drop Amid HIV Testing Market Shifts
Event summary
- Trinity Biotech expects Q4 2025 revenue of $11.5M–$12.5M, down from $15.9M in Q4 2024 due to HIV testing market disruptions and manufacturing transitions.
- The company secured regulatory approval in February 2026 for outsourcing Uni-Gold™ HIV test production, a key part of its Comprehensive Transformation Plan.
- TrinScreen™ HIV sales surged from $0.4M in Q4 2023 to $3.2M in Q4 2024 but face revenue variability due to global health procurement timing.
- Premier Hb9210 HbA1c system received IFCC Gold Classification for 2026, with expanded regulatory clearances for high-capacity HbA1c column system rollout.
The big picture
Trinity Biotech's revenue decline reflects broader disruptions in global HIV testing markets and its own strategic shift to outsourced manufacturing. The company's focus on operational transformation and product innovation aligns with industry trends toward cost efficiency and digital health solutions. Success will depend on executing its Comprehensive Transformation Plan while navigating volatile procurement cycles in the HIV testing segment.
What we're watching
- Revenue Variability
- How the shift to outsourced manufacturing will affect quarterly revenue consistency in 2026.
- HIV Testing Demand
- Whether renewed global HIV testing demand can sustain rapid HIV test revenue growth.
- Diabetes Market Growth
- The pace at which the Premier Hb9210 system can gain traction in US and Brazil markets.
Related topics